Durect out-li­cens­es anal­gesic Posimir to Irish biotech in $136M deal; Ar­cutis gets 9-fig­ure loan to push for OK for pso­ri­a­sis cream

Cal­i­for­nia’s Durect has made a deal with a biotech lo­cat­ed all the way across the pond — in Ire­land.

The two biotechs an­nounced a li­cens­ing deal yes­ter­day: Durect is out-li­cens­ing Posimir, an FDA-ap­proved lo­cal anal­gesic for post-sur­gi­cal pain, to In­no­coll, a sub­sidiary of Gur­net Point Cap­i­tal. The agree­ment in­cludes giv­ing In­no­coll ex­clu­sive de­vel­op­ment and com­mer­cial­iza­tion rights to the anal­gesic in the Unit­ed States.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER